The latest price target for Nektar Therapeutics (NASDAQ:NKTR) was reported by HC Wainwright & Co. on February 25, 2025. The analyst firm set a price target for $6.50 expecting NKTR to rise to within 12 months (a possible 673.81% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Nektar Therapeutics (NASDAQ:NKTR) was provided by HC Wainwright & Co., and Nektar Therapeutics reiterated their buy rating.

The last upgrade for Nektar Therapeutics happened on November 9, 2023 when TD Cowen raised their price target to N/A. TD Cowen previously had a market perform for Nektar Therapeutics.

The last downgrade for Nektar Therapeutics happened on February 24, 2023 when Jefferies changed their price target from $3.2 to $1.5 for Nektar Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nektar Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nektar Therapeutics was filed on February 25, 2025 so you should expect the next rating to be made available sometime around February 25, 2026.

While ratings are subjective and will change, the latest Nektar Therapeutics (NKTR) rating was a reiterated with a price target of $6.50 to $6.50. The current price Nektar Therapeutics (NKTR) is trading at is $0.84, which is out of the analyst’s predicted range.